Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw gains after beating third-quarter profit estimates, but lowering its full-year guidance. The drugmaker is gaining momentum from its diabetes drug Mounjaro, though it still lacks regulatory approval for obesity treatment.
Yahoo Finance's Diane King Hall and Brad Smith break down all the details.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Subscribe to Yahoo Finance: [ Ссылка ]

About Yahoo Finance:
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more.
To learn more about Yahoo Finance Plus please visit: [ Ссылка ]

Connect with Yahoo Finance:
Get the latest news: [ Ссылка ]
Find Yahoo Finance on Facebook: [ Ссылка ]
Follow Yahoo Finance on Twitter: [ Ссылка ]
Follow Yahoo Finance on Instagram: [ Ссылка ]
Follow Yahoo Finance Premium on Twitter: [ Ссылка ]

свернуть